Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts

Publication | Open Access

DOI Full Paper Access

Citations

References

2024

Year

Dathan M. Byonanebye, Mark N. Polizzotto, Fernando Maltêz, Andri Rauch, Katharina Grabmeier‐Pfistershammer, Ferdinand Wit, Stéphane De Wit, Antonella Castagna, Antonella d’Arminio Monforte, Cristina Mussini,

The Lancet HIV

Respond Consortium CohortsHypertensionPreventive MedicineCardiovascular EpidemiologyCardiovascular DiseaseTreatment And PreventionAntihypertensive TherapyGlobal HealthAntiviral TherapyRiskPharmacotherapyTenofovir AlafenamideHivPublic HealthMedicineEpidemiologyIntegrase Strand-transfer Inhibitors